Johnson & Johnson (ETR: JNJ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 343.97B |
| Revenue (ttm) | 78.55B |
| Net Income (ttm) | 13.15B |
| Shares Out | n/a |
| EPS (ttm) | 5.41 |
| PE Ratio | 26.15 |
| Forward PE | n/a |
| Dividend | 4.54 (3.18%) |
| Ex-Dividend Date | Feb 18, 2025 |
| Volume | 3,587 |
| Average Volume | 3,894 |
| Open | 143.46 |
| Previous Close | 142.68 |
| Day's Range | 141.70 - 143.46 |
| 52-Week Range | 132.78 - 154.00 |
| Beta | 0.52 |
| RSI | 54.93 |
| Earnings Date | Jan 22, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]
Financial Performance
In 2023, Johnson & Johnson's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.
Financial numbers in USD Financial StatementsNews
ATTENTION JNJ SHAREHOLDERS: Investors who lost money on Johnson & Johnson are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / January 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible viol...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ...
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
These eleven large-cap stocks were the best performers in the last week. Are they in your portfolio? Intra-Cellular Therapies Inc. (NASDAQ: ITCI) stock surged 33.02% after Johnson & Johnson (NYSE: JN...
Earnings week ahead: JNJ, NFLX, AAL, UAL, AXP, ABT, VZ, PG, and more
Netflix, Procter & Gamble, Johnson & Johnson Report Results In Holiday-Shortened Week
Stay ahead of the market with Seeking Alpha's Wall Street Week Ahead newsletter.
Shareholders That Lost Money on Johnson & Johnson (JNJ) Should Contact Levi & Korsinsky About Securities Fraud Investigation - JNJ
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible...
Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ...
Technology rallies as healthcare retreats: Exploring today's market dynamics
Sector Overview Today, the U.S. stock market showcases a remarkable resurgence in the technology sector, juxtaposed against a noticeable pullback in healthcare. Leading the tech charge are giants like...
Shareholder Rights Advocates at Levi & Korsinsky Investigate Johnson & Johnson (JNJ) Regarding Possible Securities Fraud Violations
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning pos...
Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves
Johnson & Johnson has underperformed its lerge-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Even though JNJ has displayed an improvingtrack record of beating consensus...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Investors to Connect
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ...
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable di...
U.S. Cancer Biopsy Market and Competition Analysis, 2025-2030, Featuring Key Players - BD, IZI Medical Products, Johnson & Johnson Services, Argon Medical Devices, Spectra Medical Devices & More
Blood-Based Multi-Cancer Early Detection (MCED) Technologies Poised to Offer Lucrative Opportunities Blood-Based Multi-Cancer Early Detection (MCED) Technologies Poised to Offer Lucrative Opportunitie...
Johnson & Johnson (JNJ) likely to report mixed results for Q4 2024
Johnson & Johnson (NYSE: JNJ) is set to publish its December-quarter report on January 22, amid expectations for mixed results. The company, which has faced both challenges and tailwinds in […] The po...
Buy 3 'Safer' Dividend Kings Of 25 From 53 For January
“A Dividend King [is] a stock with 50 or more consecutive years of dividend increases.”—suredividend.com. 53 Divided Kings, screened as of January 10, 2025, represented all eleven Morningstar Sectors....
JNJ ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Johnson & Johnson
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible viol...
JNJ ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Johnson & Johnson
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible viol...
Johnson & Johnson Initiates FDA Submission for Innovative Bladder Cancer Treatment
Johnson & Johnson Initiates FDA Submission for Innovative Bladder Cancer Treatment
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). In...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). Investors who purchased J&J securities are encour...
JNJ ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Johnson & Johnson Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible viol...
JNJ ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Johnson & Johnson Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible viol...
New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Application accepted for U.S. FDA Real-Time Oncology Review (RTOR) based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1 RARITAN, N.J. , Jan. 15, 2025 ...
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health Care Conference.
Looking Into Johnson & Johnson's Recent Short Interest
Johnson & Johnson's (NYSE: JNJ) short percent of float has fallen 6.85% since its last report. The company recently reported that it has 16.46 million shares sold short , which is 0.68% of all regula...